Gene and Cell Therapy – News and Features

Researchers developed a dual-vector "zip-sorting" system, doubling the genetic capacity of CAR T cells to combat tumor resistance. This enables T cells to target multiple antigens, reduce exhaustion via switch receptors and resist immune suppression.

A chemogenetic tool could form the basis of a gene therapy for chronic pain by turning off pain receptors.

City of Hope researchers discovered YTHDF2, a protein enabling blood cancers to evade CAR T cell therapy by hiding critical antigens. They developed CCI-38, a compound that suppresses YTHDF2, enhancing CAR T therapy's success.

McGill researchers discovered that K884, an experimental drug, enhances muscle stem cell repair in Duchenne muscular dystrophy (DMD). Unlike gene therapies, K884 targets DMD-affected cells regardless of the mutation.

Cell and gene therapies are revolutionizing medicine. Looking to 2025, advancements in allogeneic therapies, streamlined autologous processes and broader applications promise increased accessibility and innovation in treating complex diseases.

In a new study, scientists combined strategies to deliver energy-disrupting gene therapy using nanoparticles manufactured to zero in only on cancer cells, with experiments showing the targeted therapy effective in mice.

This article explores the latest techniques and workflows for purification across biopharmaceuticals including vaccines, monoclonal antibody therapies and gene therapies.

This article explores some of the challenges in developing cell lines for therapeutics, such as cell line stability, and how they are being addressed.

A new gene therapy can reverse the effects of heart failure and restore heart function in a large animal model.

New potential therapeutic targets have been identified for diabetic kidney disease, the leading cause of kidney failure worldwide.